



Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer

Pia Charlotte Kræmer, Hjørdis Hjalting Schmidt & Morten Ladekarl

INTRODUCTION

Worldwide, pancreatic cancer (PC) ranks 13th in cancer incidence, but 8th as a cause of cancer death. For more than a decade, the reference regimen for palliative treatment of PC has been gemcitabine. In 2011, a randomised trial published by the PRODRIGE Intergroup showed an increase in median overall survival from 6.8 to 11.1 months in patients treated with FOLFIRINOX as compared with gemcitabine.

MATERIAL AND METHODS

A total of 16 patients treated with FOLFIRINOX as first-line therapy for inoperable PC were included for this retrospective study. FOLFIRINOX was administered unmodified according to the PRODRIGE trial, and up to 12 cycles were planned with a computed tomography (CT) for every fourth cycle.

RESULTS

Eleven patients completing at least four cycles of chemotherapy and therefore evaluable for response were assessed by review of CT. Partial response (PR) was shown after four cycles in four patients, whereas seven patients had stable disease, which resulted in an objective response rate of 36%. After eight cycles, one additional patient obtained a PR. No complete responders or patients with progressive disease were recorded.

Toxicity was assessed by review of medical records with respect to toxic effects requiring interruption of therapy, admission of the patient or prolonged admission.

CONCLUSION

Toxicity was shown to be a problem only during the first five cycles, and no patients were admitted to hospital due to toxicity after having received more than five cycles.

The six-month-survival was 81%.

FUNDING: not relevant.

TRIAL REGISTRATION: not relevant.

CORRESPONDENCE: Pia Charlotte Kræmer. E-mail: piacka@dadlnet.dk

CONFLICTS OF INTEREST: none. Disclosure forms provided by the authors are available with the full text of this article at www.danmedj.dk.

REFERENCE: Dan Med J 2014;61(4):A4819

FROM: Department of Oncology, Aarhus University Hospital



PUBLICERET PÅ UGESKRIFTET.DK
28. APRIL 2014

Diagnostiske kriterier og behandlingsmuligheder ved idiopatisk pulmonal fibrose

Elisabeth Bendstrup, Charlotte Hyldgaard & Ole Hilberg

Mulig sammenhæng mellem marginal parodontitis og iskæmisk hjertesygdom

Gorm Mørk Hansen, Palle Holmstrup, Tim Tolker-Nielsen et al

Diagnostik af funktionelle anfald hos børn og unge

Bianca Taaning Wichaidit, Charlotte Ulrikka Rask & John R. Østergaard

Skadestuelægers kendskab til battered child syndrome er mangelfuldt

Jenny Korsgaard Villadsen, Ann Buhl Bersang, Rikke Thorninger, Bjarne Møller-Madsen & Ole Rahbek



PUBLICERET PÅ UGESKRIFTET.DK
22. APRIL 2014

Kæmpecellearteritis diagnosticeret ved hjælp af PET-CT

Cæcilie Crawley Larsen, Søren Schifter & Steen Joop Bonnema

Svær hypoglykæmi og dumpingsyndrom efter fedmekirurgi

Joan Bach Nielsen, Dorthe Møller & Bjørn Richelsen

Truncus coeliacus-kompressionssyndrom er en sjælden årsag til mesenterial iskæmi

Ivana Jevtic & Janus Mølgaard Christiansen

Pituitær apopleksi hos en ung kvinde

Anna Lewis, Anne Elisabeth Jarløv, Kirsten Holm & Line Cleemann

Kejsersnit kan have konsekvenser på lang sigt for både mor og barn

Anna J.M. Aabakke, Lone Krebs & Jacob A. Lykke